

PRESS RELEASE


innate pharma

NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT FEBRUARY 28, 2007

Marseilles, March 19, 2007

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (*Autorité des Marchés Financiers*, or "AMF") charter, Innate Pharma SA, a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, releases its total number of shares outstanding as well as its voting rights as at February 28, 2007:

Total number of shares outstanding:	25.111.284
Voting rights:	25.111.284



PRESS RELEASE

innate pharma

About Innate Pharma:

Founded in 1999 and funded by reference venture capitalists up to its IPO on Euronext in Paris in 2006, Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) is a biopharmaceutical company developing first-in-class* drugs targeting innate immunity.

The pioneering work of Innate Pharma's scientific founders and research groups has led to the development of three product platforms (gamma delta T cells, NK cells and TLR), each directly or indirectly validated in clinical oncology settings.

Besides cancer, Innate Pharma's drug candidates have development potential in the treatment of infectious disease and chronic inflammation. The company's most advanced molecule is in Phase II clinical trials in cancer.

With its strong scientific position in innate immunity pharmacology, its robust intellectual property portfolio and its R&D expertise, Innate Pharma intends to become a leading player in the rapidly growing market of immunotherapeutics.

Based in Marseilles, France, Innate Pharma had 67 employees as at December 31, 2006.

Learn more about Innate-Pharma at www.innate-pharma.com

Practical Information about Innate Pharma shares:

ISIN code FR0010331421
Ticker code IPH

Disclaimer:

This press release, and the information contained herein, does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

For any additional information, please contact:

Innate Pharma

Stéphane Boissel, CFO
Tel. : +33 (0)4 96 19 05 58
stephane.boissel@innate-pharma.fr

Alize Public Relations

Caroline Carmagnol
Tel. : +33 (0)6 64 18 99 59
caroline.carmagnol@wanadoo.fr

* with new mechanisms of action.